Pharmaceuticals · Nov 18, 2026
Lyophilized Mesenchymal Stromal Cell-Derived Products in Regenerative Medicine: A Systematic Review of Biological Activity, Stability, Safety, and Therapeutic Effects
By Sadykov B, Baigenzhin A, Ganina A et al.
Background/Objectives: Lyophilization may facilitate storage and distribution of mesenchymal stromal cell (MSC)-derived products. This systematic review assessed biological activity, storage stability, safety, and therapeutic effects of lyophilized MSC-derived products in regenerative medicine. Methods: PubMed, Scopus, and Web of Science Core Collection were searched through 28 August 2026. Eligible English-language original studies included in vivo animal or human therapeutic evaluations. The review was registered in PROSPERO (CRD420261426429) and reported following PRISMA 2020. Two reviewers independently selected studies, extracted data, and assessed risk of bias using SYRCLE, RoB 2, or ROBINS-I according to study design. Heterogeneity precluded meta-analysis; findings were synthesized narratively. Results: Thirty-nine studies were included from 884 records; only one contained a human interventional component. Products included conditioned medium, secretome, extracellular vesicles, and whole-cell or synthetic preparations. Sixteen studies evaluated biological activity or stability: 12 directly compared lyophilized and fresh or non-lyophilized products, whereas four assessed post-lyophilization activity without a fresh or non-lyophilized comparator. Retention depended on product formulation and processing conditions, and storage-stability evidence was limited. Twelve studies provided safety evidence; no major systemic toxicity signal emerged, although concentration-dependent cytotoxicity in vitro and transient local reactions occurred. Most studies reported improvement in at least one regenerative or functional outcome, with neutral or mixed findings in some applications. Incomplete reporting of randomization and blinding limited confidence in the evidence. Conclusions: Some lyophilized MSC-derived products retain biological properties and exhibit therapeutic activity, predominantly in preclinical models. Evidence is insufficient to establish clinical efficacy or long-term safety. Translation requires standardized manufacturing, validated potency and storage-stability testing, systematic safety assessment, and well-designed human studies.